Overexpression of glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor-1 inhibits tissue factor activity

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 6, 2003, Pages 539-544

  Ott, Ilka ^a   Vukovich, Ruth ^a   Schömig, Albert ^a   Neumann, Franz Josef ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atherosclerosis; Endothelial receptors; Experimental; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; DECAY ACCELERATING FACTOR; GLYCOSYL PHOSPHATIDYLINOSITOL; HYBRID PROTEIN; LIPOSOME; PHOSPHATIDYLINOSITOL; PLACENTA PROTEIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; ASSAY; BLADDER CARCINOMA; BLOOD CLOTTING; CELL LINE; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEASUREMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WILD TYPE;

ANTICOAGULANTS; CELL LINE, TUMOR; CHROMOGENIC COMPOUNDS; FACTOR XA; GENE THERAPY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; LIPOPROTEINS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; TRANSFECTION;

EID: 0041330489     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200309000-00004     Document Type: Article

References (31)

1. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997; 78:401-405.
2. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81:1-41.
3. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
4. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X [published erratum appears in Lab Invest 1997; 76:297-299]. Lab Invest 1996; 75:451-461.
5. Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar W, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20:1362-1373.
6. Moreno PR, Bernardi VH, Lopez-Cuellar J, Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94:3090-3097.
7. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99:1780-1787.
8. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95:594-599.
9. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95:1773-1781.
10. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar W, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17:2964-2974.
11. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20:874-882.
12. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29:1515-1519.
13. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133:293-304.
14. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660.
15. Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, Saito H. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 1996; 271:5914-5920.
16. Warshawsky I, Herz J, Broze GJ, Schwartz AL. The low density lipoprotein receptor-rerated protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 1996; 271:25873-25879.
17. Fernandez-Oritz A, Badmin J, Falk E. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562-1569.
18. Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91:619-622.
19. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabibts. Circulation 1995; 92:3323-3330.
20. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92:3041-3050.
21. Paswashe AB, Golino P, Ambrosio G. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74:56-63.
22. Platt JL, Verccelotti GM, Lindman BJ, Oegema TR, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells, implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171:1363-1368.
23. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinolysis 1994; 5:755-760.
24. Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84:821-827.
25. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96:646-652.
26. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101:289-295.
27. Ott I, Malcouvier V, Schomig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002; 105:279-281.
28. Gando S, Kameue T, Morimoto Y, Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30:1729-1734.
29. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74:90-93.
30. Riesbeck K, Dorling A, Kemball-Cook G, McVey JH, Jones M, Tuddenham EG, Lechler RI. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface. Thromb Haemost 1997; 78:1488-1494.
31. Medorf ME, Nagarajan S, Tykocinski ML. Cell-surface engineering with GPI-anchored proteins. FASEB J 1996; 10:574-581.